Evaluation of Rhodiola rosea L. extract on affective and physical signs of nicotine withdrawal in mice

Journal of Psychopharmacology

Volumn 25, Issue 3, 2011, Pages 402-410

  Mattioli, Laura ^a   Perfumi, Marina ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

abstinence; anxiety; dependence; nicotine; Rhodiola rosea; somatic signs; withdrawal

Indexed keywords

RHODIOLA ROSEA EXTRACT;

ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; BODY TREMOR; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FOREFOOT; HEAD MOVEMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JUMPING; LOCOMOTION; MALE; MASTICATION; MEDICINAL PLANT; MOUSE; NONHUMAN; PAW TREMOR; PRIORITY JOURNAL; PTOSIS; REFLEX; RHODIOLA ROSEA; SMOKING CESSATION; TOBACCO DEPENDENCE; TREMOR; WITHDRAWAL SYNDROME;

ANIMALS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; PLANT EXTRACTS; RHODIOLA; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 79952173838     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109348166     Document Type: Article

References (79)

1. Abidov M., Crendal F., Grachev S., Seifulla R., Ziegenfuss T. (2003) Effect of extracts from Rhodiola rosea and Rhodiola crenulata (Crassulaceae) roots on ATP content in mitochondria of skeletal muscles. B Exp Biol Med 136: 585-587. (Pubitemid 39137285)
2. Balfour DJ (2009) The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb Exp Pharmacol 192: 209-233.
3. Barik J., Wonnacott S (2009) Molecular and cellular mechanisms of action of nicotine in the CNS. Handb Exp Pharmacol 192: 173-207.
4. Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol 49: 57-71.
5. Biala G., Weglinska B. (2005) Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channels antagonists. Pharmacol Res 51: 483-488. (Pubitemid 40321018)
6. Bourin M., Hascoet M. (2003) The mouse light/dark box test. Eur J Pharmacol 463: 55-65. (Pubitemid 36205072)
7. Brown RP, Gerbarg PL, Ramazanov Z. (2002) Rhodiola rosea. A phytomedicinal overview. HerbalGram 56: 40-52.
8. Buchhalter AR, Fant RV, Henningfield JE (2008) Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 68: 1067-1088. (Pubitemid 351693676)
9. Carrozzi L., Pistelli F., Viegi G. (2008) Pharmacotherapy for smoking cessation. Ther Adv Respir Dis 2: 301-317.
10. Carton S., Le Houezec J., Lagrue G., Jouvent R. (2002) Early emotional disturbances during nicotine patch therapy in subjects with and without a history of depression. J Affect Disorders 72: 195-199. (Pubitemid 35007363)
11. Catania MA, Firenzuoli F., Crupi A., Mannucci C., Caputi AP, Calapai G. (2003) Hypericum perforatum attenuates nicotine withdrawal signs in mice. Psychopharmacology (Berlin) 169: 186-189. (Pubitemid 37129970)
12. Chen QG, Zeng YS, Qu ZQ, et al. (2009) The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. Phytomedicine. doi:10.1016/j.phymed.2009.03.011.
13. Cohen C., Perrault G., Griebel G., Soubrié P. (2005) Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30: 145-155. (Pubitemid 40024408)
14. Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1: 11-20.
15. Crawley J., Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Be 13: 167-170. (Pubitemid 11225713)
16. Dani JA, De Biasi M. (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Be 70: 439-446. (Pubitemid 34131638)
17. De Biasi M., Salas R. (2008) Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp Biol Med (Maywood) 233: 917-929.
18. Dhawan K., Kumar S., Sharma A. (2002) Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata Linneaus in mice. Addict Biol 7: 435-441. (Pubitemid 35402518)
19. Dierker LC, Avenevoli S., Stolar M., Merikangas KR (2002) Smoking and depression: an examination of mechanisms of comorbidity. Am J Psychiat 159: 947-953. (Pubitemid 34586939)
20. Fagerström K., Hughes J. (2008) Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat 4: 353-363. (Pubitemid 351711930)
21. Fiore MC, Jae'n CR, Baker TB, et al. (2008) Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. 2008 PHS Guideline Update Panel, Liaisons, and Staff Respir Care 53: 1217-1222.
22. Fowler JS, Logan J., Wang GJ, Volkow ND (2003) Monoamine oxidase and cigarette smoking. Neurotoxicology 24: 75-82. (Pubitemid 36091163)
23. Galanti LM (2008) Tobacco smoking cessation management: integrating varenicline in current practice. Vasc Health Risk Manag 4: 837-845.
24. George O., Ghozland S., Azar MR, et al. (2007) CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. P Natl Acad Sci USA 104: 17198-17203. (Pubitemid 350211014)
25. George TP, O'Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25: 42-48. (Pubitemid 38081281)
26. George TP, Weinberger AH (2008) Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther 83: 619-621. (Pubitemid 351417061)
27. Guillem K., Vouillac C., Azar MR, et al. (2005) Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 25: 8593-8600. (Pubitemid 41362035)
28. Guillem K., Vouillac C., Azar MR, et al. (2006) Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci 24: 3532-3540. (Pubitemid 44952618)
29. Guillem K., Vouillac C., Koob GF, Cador M., Stinus L. (2008) Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. Biol Psychiat 63: 158-163. (Pubitemid 350299328)
30. Hascoet M., Bourin M., Dhonnchadha BA (2001) The mouse lightdark paradigm: a review. Prog Neuro-psychoph 25: 141-166.
31. Hildebrand BE, Nomikos GG, Hertel P., Schilstrom B., Svensson TH (1998) Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats display a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779: 214-225. (Pubitemid 28039954)
32. Holm KJ, Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59: 1007-1024. (Pubitemid 30232332)
33. Hughes JR, Hatsukami DK, Skoog K. (1986) Physical dependence on nicotine gum: a placebo substitution trial. J Amer Med Assoc 255: 3277-3279. (Pubitemid 16122591)
34. Isola R., Vogelsberg V., Wemlinger TA, Neff NH, Hadjiconstantinou M. (1999) Nicotine abstinence in the mouse. Brain Res 850: 189-196.
35. Kelly GS (2001) Rhodiola rosea: a possible plant adaptogen. Altern Med Rev 6: 293-302. (Pubitemid 32591865)
36. Kenny PJ, Markou A. (2001) Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Be 70: 531-549. (Pubitemid 34131647)
37. Koob GF, Le Moal M. (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97-129.
38. Kota D., Martin BR, Damaj MI (2008) Age-dependent differences in nicotine reward and withdrawal in female mice. Psychopharmacology (Berlin) 198: 201-210.
39. Kurkin VA, Zapesochnaya GG (1986) Chemical composition and pharmacological properties of Rhodiola rosea. Chem Pharm J (Moscow) 20: 1231-1244.
40. Lazarova MB, Petkov VD, Markovska VL, Petkov VV, Mosharrof A. (1986) Effects of meclofenoxate and Extr. Rhodiolae roseae L. on electroconvulsive shock-impaired learning and memory in rats. Method Find Exp Clin 8: 547-552. (Pubitemid 17208021)
41. Lee SY, Song DK, Jang CG (2003) Effects of Coptis japonica on morphine-induced conditioned place preference in mice. Arch Pharm Res 26: 540-544.
42. Lerman C., Audrain J., Orleans CT, et al. (1996) Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav 21: 9-19. (Pubitemid 26080739)
43. Lerman C., Roth D., Kaufmann V., et al. (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depen 67: 219-223. (Pubitemid 34722410)
44. Leroy C., Bragulat V., Berlin I., et al. (2009) Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clin Psychopharm 29: 86-88.
45. Leventhal AM, Ramsey SE, Brown RA, Lachance HR, Kahler CW (2008) Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res 10: 507-517. (Pubitemid 351385832)
46. Lewis A., Miller JH, Lea RA (2007) Monoamine oxidase and tobacco dependence. Neurotoxicology 28: 182-195. (Pubitemid 46187252)
47. Lillington GA, Leonard CT, Sachs DP (2000) Smoking cessation. Techniques and benefits. Clin Chest Med 21: 199-208.
48. Linh PT, Kim YH, Hong SP, Jian JJ, Kang JS (2000) Quantitative determination of salidroside and tyrosol from the underground part of Rhodiola rosea by high performance liquid chromatography. Arch Pharm Res 23: 349-352.
49. Malin DH (2001) Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Be 70: 551-559. (Pubitemid 34131648)
50. Malin DH, Goyarzu P (2009) Models of nicotine withdrawal syndrome. Handb Exp Pharmacol 192: 401-434.
51. Mathers CD, Loncar D. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
52. Mattioli L., Funari C., Perfumi M (2009) Effects of Rhodiola rosea L. extract on behavioural and physiological alterations induced by chronic mild stress in female rats. J Psychopharmacol 23: 130-142.
53. Mattioli L., Perfumi M. (2007) Rhodiola rosea L. extract reduces stress-and CRF-induced anorexia in rats. J Psychopharmacol 21: 742-750. (Pubitemid 47437914)
54. Mitrouska I., Bouloukaki I., Siafakas NM (2007) Pharmacological approaches to smoking cessation. Pulm Pharmacol Ther 20: 220-232. (Pubitemid 46240949)
55. Nestler EJ (2001) Molecular neurobiology of addiction. Am J Addict 10: 201-217. (Pubitemid 32879087)
56. Panagis G., Hildebrand BE, Svensson TH, Nomikos GG (2000) Selective cfos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamineprecipitated nicotine withdrawal syndrome. Synapse 35: 15-25.
57. Panossian A., Nikoyan N., Ohanyan N., et al. (2008) Comparative study of Rhodiola preparations on behavioural despair of rats. Phytomedicine 15: 84-91.
58. Perfumi M., Mattioli L. (2007) Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytother Res 21: 37-43. (Pubitemid 46173906)
59. Quattrocki E., Baird A., Yurgelun-Todd D. (2000) Biological aspects of the link between smoking and depression. Harvard Rev Psychiat 8: 99-110. (Pubitemid 30659210)
60. Ross S., Williams D. (2005) Bupropion: risks and benefits. Expert Opin Drug Saf 4: 995-1003. (Pubitemid 41671598)
61. Sahraei H., Fatemi SM, Pashaei-Rad S., Faghih-Monzavi Z., Salimi SH, Kamalinegad M. (2006) Effects of Papaver rhoeas extract on the acquisition and expression of morphine-induced conditioned place preference in mice. J Ethnopharmacol 103: 420-424. (Pubitemid 43143378)
62. Saratikov A., Marina TF, Fisanova LL (1978) Effect of golden root extract on processes of serotonin synthesis in the CNS. J Biol Sci 6: 142.
63. Shiffman S., Dresler CM, Rohay JM (2004) Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99: 83-92. (Pubitemid 38142226)
64. Shiffman S., Shadel WG, Niaura R., et al. (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berlin) 166: 343-350. (Pubitemid 36469936)
65. Stancheva SL, Mosharrof A. (1987) Effect of the extract of Rhodiola rosea L. on the content of the brain biogenic monoamines. Medecine Physiologie Comptes Rendus de l'Academie Bulgare des Sciences 40: 85-87.
66. Stead LF, Hughes JR (2000) Lobeline for smoking cessation. Cochrane DB Syst Rev 2: CD000124.
67. Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. Psychopharmacology 117: 2-10.
68. Stolerman IP, Shoaib M. (1991) The neurobiology of tobacco addiction. Trends Pharmacol Sci 12: 467-473.
69. Talhout R., Opperhuizen A., Van Amsterdam JG (2007) Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharm 17: 627-636. (Pubitemid 47268752)
70. Tapper AR, McKinney SL, Nashmi R., et al. (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306: 1029-1032. (Pubitemid 39482905)
71. Thompson GH, Hunter DA (1998) Nicotine replacement therapy. Ann Pharmacother 32: 1067-1075. (Pubitemid 28498468)
72. US Department of Health and Human Sciences (1988) The health consequences of smoking: nicotine addiction. A report of the Surgeon General Maryland: Office on Smoking and Health.
73. Uzbay TI (2008) Hypericum perforatum and substance dependence: a review. Phytother Res 22: 578-582. (Pubitemid 351716543)
74. Van Diermen D., Marston A., Bravo J., Reist M., Carrupt PA, Hostettmann K (2009) Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol 122: 397-401.
75. Wang S., You XT, Wang FP (1992) HPLC determination of salidroside in the roots of Rhodiola genus plants. Yao Xue Xue Pao 27: 849-852.
76. West RJ, Russel MAH (1985) Effects of withdrawal from long term nicotine gum use. Psychol Med 15: 891-893. (Pubitemid 16213871)
77. WHO Report on the Global Tobacco Epidemic (2008) The MPOWER Package. Geneva, World Health Organization. Available at: http://www.who.int/tobacco/ mpoewer/mpower-report.
78. Wilkes S. (2008) The use of bupropion SR in cigarette smoking cessation. Intern J Chron Obstruct Pulmon Dis 3: 45-53. (Pubitemid 351523717)
79. Yoshikawa M., Shimada H., Shimoda H., Murakami N., Yamahara J., Matsuda H. (1996) Bioactive constituents of Chinese natural medicines. II. Rhodiolae radix. (1). Chemical structures and anti allergic activity of rhodiocyanosides A and B from the underground part of Rhodiola quadrifida (Pal1.) Fisch. et Mey. (Crassulaceae). Chem and Pharm Bull (Tokyo) 44: 2086-2091. (Pubitemid 26396758)